Articles tagged "Kidney transplantation"

2015 American Transplant Congress
Renal Transplantation in Aged Over 60 Years Demonstrates Compatible Clinical Outcomes to Younger Recipients
H. Cho,¹ H. Kim,¹ C. Baeck,¹ H. Yu,¹ D.-J. Han,² M. Jo,³ S.-K. Park.¹
¹Division of Nephrology, Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea; ²Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea; ³Department of Preventive Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Introduction: The aim of this study was comparing clinical outcomes of kidney transplantation between aged over 60 years and younger recipientsMethods: From 1993 to 2013,…
2015 American Transplant Congress
Perfusion Disturbances and Local Infarctions After Experimental Kidney Transplantation Corralte With the Duration of Cold Ischemia Time
S. Rong,¹ R. Chen,¹ M. Meier,⁴ B. Hensen,² H. Haller,¹ K. Hueper,² F. Gueler.¹
¹Nephrology, Hannover Medical School, Hannover, Germany; ²Radiology, Hannover Medical School, Hannover, Germany; ³Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada; ⁴Imaging Center, Hannover Medical School, Hannover, Germany.
Background: Kidney transplantation in mice is challenging but offers good translational models to study mechanisms of disease. In this study allogenic and isogenic kidney transplantation…
2015 American Transplant Congress
Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients
Y. Watarai,¹ N. Akutsu,² K. Saito,³ Y. Nakagawa,³ O. Kamisawa,⁴ T. Kenmochi.⁵
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Surgery, Chiba-East Hospital, Chiba, Japan; ³Urology, Niigata University, Niigata, Japan; ⁴Medical Division, Novartis Pharma K.K., Tokyo, Japan; ⁵Transplant Surgery, Fujita Health University, Toyoake, Japan.
Purpose: To evaluate the long-term efficacy and safety of everolimus (EVR) plus reduced cyclosporine (rCsA) compared to mycophenolate mofetil (MMF) plus standard cyclosporine at 24…
2015 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid (MPA) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial
P. Romano,¹ F. Agena,² P. Ebner,¹ A. Triboni,² F. Ramos,² N. Galante,² F. Lemos,² N. Sumita,¹ E. David-Neto.²
¹Division of Central Laboratory, – Hospital das Clinicas – University of São Paulo School of Medicine, Sao Paulo, Brazil; ²Renal Transplantation Service, – Hospital das Clinicas – University of São Paulo School of Medicine, Sao Paulo, Brazil.
Elderly (≥60years) recipients are nowadays receiving renal transplants more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include old…
2015 American Transplant Congress
Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation
D. Halleran,¹ S. Schurman, T. Welch, V. Whittaker.
¹Surgery, State University New York Upstate Medical University, Syracuse, NY; ²Pediatric Nephrology, State University New York Upstate Medical University, Syracuse, NY.
Purpose: We report the outcomes from single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative day…
2015 American Transplant Congress
Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis
H. Kaminski,¹ L. Couzi,^1,2 I. Garrigue,^3,4 J. Déchanet-Merville,² P. Merville.^1,2
¹Nephrologie-Transplantation-Dialyse, CHU Bordeaux, Bordeaux, France; ²Unité Mixte de Recherche 5164, Centre National de la Recherche Scientifique, Bordeaux, France; ³Laboratoire de Virologie, CHU Bordeaux, Bordeaux, France; ⁴Unité Mixte de Recherche 5234, Centre National de la Recherche Scientifique, Bordeaux, France.
Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal…
2015 American Transplant Congress
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of Graft Failure and Mortality Among Kidney Transplant Recipients
P. Clayton,^1,2,3 W. Lim,^1,4 S. Chadban.^1,2,3
¹Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australia; ²Transplantation, Royal Prince Alfred Hospital, Sydney, Australia; ³Sydney Medical School, University of Sydney, Sydney, Australia; ⁴Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
Purpose: Graft loss and death are generally late events after kidney transplantation, and trials designed to assess the impact of interventions on these outcomes are…
2015 American Transplant Congress
Should Only Active Candidates Define the EPTS Top 20% in the New Kidney Allocation System (KAS)?
D. Stewart,¹ A. Kucheryavaya,¹ G. Boyle,¹ M. Aeder,² R. Formica.³
¹UNOS, Richmond, VA; ²Univ Hosp Case Med Ctr, Cleveland, OH; ³Yale, New Haven, CT.
Background: The 20% of kidney candidates with the highest Estimated Post-Transplant Survival (EPTS) receive priority for a high longevity kidney in the Organ Procurement and…
2015 American Transplant Congress
Immunoglobulin G Donor-Specific Anti-HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
D. Viglietti,^1,2 C. Bentlejewski,³ J.-P. Duong van Huyen,^4,2 D. Vernerey,^5,2 O. Aubert,² J. Verine,¹ X. Jouven,² C. Legendre,⁴ D. Glotz,¹ A. Loupy,^2,4 A. Zeevi,³ C. Lefaucheur.^1,2
¹Saint-Louis Hospital, Paris, France; ²Paris Translational Research Center for Organ Transplantation - INSERM U970, Paris, France; ³University of Pittsburgh Medical Center, Pittsburgh; ⁴Necker Hospital, Paris, France; ⁵CHRU de Besançon, Besançon, France.
Experimental and clinical data suggest that antibodies have different pathogenicities according to their IgG subclasses. We investigated the association between IgG subclasses of circulating anti-HLA…
2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
A. Vo, J. Choi, I. Kim, J. Kahwaji, A. Peng, R. Villicana, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…